<DOC>
	<DOCNO>NCT00007969</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make cancer cell sensitive light kill tumor cell . Photodynamic therapy may effective treat melanoma . PURPOSE : Phase I/II trial study effectiveness photodynamic therapy treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Photodynamic Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety photodynamic therapy verteporfin Detox-B adjuvant patient stage III IV melanoma . II . Determine clinical response patient treat regimen . III . Determine whether regimen induces systemic cellular humoral immune response melanoma antigens patient . IV . Determine ablation cutaneous tumor patient treat regimen . OUTLINE : This multicenter study . Patients undergo photodynamic therapy verteporfin Detox-B adjuvant . Treatment repeat every 2 week total 3 course , different melanoma lesion . Both non-treated treated tumor measure prior study month 2 , 4 , 6 . Immune profile also assess prior study month 2 , 4 , 6 . PROJECTED ACCRUAL : A total 30 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Detox adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage III IV melanoma At least 3 cutaneous tumor treatment ( treatment tumor ) AND 17 additional cutaneous , visceral , lymph node tumor response assessment ( marker tumor ) Treatment tumor must trunk , arm , leg AND 1.03.6 cm long dimension Measurable disease caliper CT scan No CNS metastases CT scan PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 2,500/mm3 Neutrophil count least 1,000/mm3 Platelet count least 50,000/mm3 Hemoglobin least 9 g/dL Hematocrit least 27 % Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST/ALT great 2 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 2 time ULN PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy immunotherapy No concurrent biologic therapy Chemotherapy : At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : No concurrent surgical removal melanoma lesion designate treatment response assessment Other : No concurrent therapy melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>